North Reading, MA, United States of America

Janice A Dominov


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2020-2024

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Janice A Dominov: Innovator in Antisense Oligonucleotide Research

Introduction

Janice A Dominov is a prominent inventor based in North Reading, MA (US). She has made significant contributions to the field of molecular biology, particularly in the development of antisense oligonucleotides aimed at addressing genetic disorders. With a total of three patents to her name, her work has the potential to impact the treatment of dysferlinopathy, a rare muscle disorder.

Latest Patents

Janice's latest patents include innovative approaches to restore dysferlin protein expression in patient cells. One of her notable patents focuses on antisense oligonucleotide compositions and methods for modifying pre-mRNA splicing in the DYSF gene. This invention addresses a novel mutation that creates a pseudoexon between exons 50 and 51. Another significant patent involves methods for altering RNA splicing in subjects with mutations in the DYSF gene, which can lead to defective splicing and subsequent muscle degeneration.

Career Highlights

Janice A Dominov is affiliated with the University of Massachusetts, where she conducts her research and develops her inventions. Her work is characterized by a strong commitment to advancing genetic therapies and improving patient outcomes for those affected by genetic disorders.

Collaborations

Janice collaborates with Robert H Brown, Jr., a fellow researcher who shares her passion for genetic research and innovation. Their partnership enhances the scope and impact of their work in the field.

Conclusion

Janice A Dominov is a trailblazer in the realm of antisense oligonucleotide research, with a focus on addressing genetic disorders. Her contributions through her patents and collaborations are paving the way for new therapeutic strategies in the treatment of dysferlinopathy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…